We also showed that the expression of FASN is regulated by SREBP1/SPREBP2 and that the combination of FASN and SREBP inhibitors enhanced the effects on both CTCL cell lines and primary SS patient cells. This evidence concerns the gene SREBF1 and synovial sarcoma.